Alkermes Inc Company Profile
✉ Email this page to a colleague
What is the competitive landscape for ALKERMES INC, and what generic alternatives to ALKERMES INC drugs are available?
ALKERMES INC has three approved drugs.
There are thirty US patents protecting ALKERMES INC drugs.
There are two hundred and twenty-four patent family members on ALKERMES INC drugs in thirty-three countries and six supplementary protection certificates in four countries.
Summary for Alkermes Inc
| International Patents: | 224 |
| US Patents: | 30 |
| Tradenames: | 3 |
| Ingredients: | 2 |
| NDAs: | 3 |
| Drug Master File Entries: | 12 |
Drugs and US Patents for Alkermes Inc
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Alkermes Inc | LYBALVI | olanzapine; samidorphan l-malate | TABLET;ORAL | 213378-004 | May 28, 2021 | RX | Yes | No | 9,517,235 | ⤷ Subscribe | ⤷ Subscribe | ||||
| Alkermes Inc | ARISTADA | aripiprazole lauroxil | SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR | 207533-001 | Oct 5, 2015 | RX | Yes | No | 10,226,458 | ⤷ Subscribe | ⤷ Subscribe | ||||
| Alkermes Inc | LYBALVI | olanzapine; samidorphan l-malate | TABLET;ORAL | 213378-003 | May 28, 2021 | RX | Yes | No | 11,185,541 | ⤷ Subscribe | ⤷ Subscribe | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Alkermes Inc
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Alkermes Inc | LYBALVI | olanzapine; samidorphan l-malate | TABLET;ORAL | 213378-001 | May 28, 2021 | 7,956,187 | ⤷ Subscribe |
| Alkermes Inc | LYBALVI | olanzapine; samidorphan l-malate | TABLET;ORAL | 213378-002 | May 28, 2021 | 8,252,929 | ⤷ Subscribe |
| Alkermes Inc | LYBALVI | olanzapine; samidorphan l-malate | TABLET;ORAL | 213378-003 | May 28, 2021 | 8,252,929 | ⤷ Subscribe |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for Alkermes Inc Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| New Zealand | 631345 | ⤷ Subscribe |
| Japan | 2014508176 | ⤷ Subscribe |
| Croatia | P20191029 | ⤷ Subscribe |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Alkermes Inc Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1675573 | 2014C/029 | Belgium | ⤷ Subscribe | PRODUCT NAME: ARIPIPRAZOLE; AUTHORISATION NUMBER AND DATE: EU/1/13/882 20131119 |
| 1675573 | 300669 | Netherlands | ⤷ Subscribe | PRODUCT NAME: ARIPIPRAZOLE; REGISTRATION NO/DATE: EU/1/13/882 20131115 |
| 1675573 | C300669 | Netherlands | ⤷ Subscribe | PRODUCT NAME: ARIPIPRAZOLE; REGISTRATION NO/DATE: EU/1/13/882 20131115 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
